Skip to main content
CG Invites Co., Ltd. logo

CG Invites Co., Ltd. — Investor Relations & Filings

Ticker · 083790 ISIN · KR7083790006 KO Manufacturing
Open in API
Filings indexed 450 across all filing types
Latest filing 2026-03-10 Regulatory Filings
Country KR South Korea
Listing KO 083790

About CG Invites Co., Ltd.

https://cginvites.com/en

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Recent filings

Filing Released Lang Actions
영업정지(자율공시)(종속회사의주요경영사항)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure regarding a subsidiary's business suspension (cessation of operations in a specific business unit). It follows the standard format for a material management event disclosure (often referred to as a 'Major Management Matter' or 'Autonomous Disclosure' in the Korean market). Since it does not fit into specific categories like M&A, dividend announcements, or financial reports, it is classified as a general regulatory filing.
2026-03-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity or individual acquires a significant stake (typically 5% or more) in a listed company. This document details the shareholding changes, the purpose of holding (management influence), and the list of special related parties. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2026-01-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a major shareholder or executive changes their stake in a company. This falls under the category of 'Director's Dealing' (DIRS) as it details personal/entity share transactions by a major shareholder.
2026-01-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This document details the acquisition of shares by a major shareholder (Invites Genomics) in the issuing company (CG Invites). In the context of financial filings, reports detailing personal or entity-level share transactions by directors, executives, or major shareholders are classified as 'Director's Dealing' (DIRS).
2026-01-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a standard regulatory filing in South Korea (DART system) used to disclose insider trading or changes in shareholding by major stakeholders. This corresponds to the 'Director's Dealing' category, as it details the acquisition of shares by a major shareholder/entity.
2026-01-19 Korean
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is a short announcement (under 1,000 characters) notifying the public of an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting, and mentions where the presentation materials will be posted. Since it is an announcement of an event rather than the presentation slides themselves, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure announcement.
2025-12-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.